Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; Berlin Institute of Health, Anna-Louisa-Karsch-Straße 2, D-10178 Berlin, Germany.
Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; Berlin Institute of Health, Anna-Louisa-Karsch-Straße 2, D-10178 Berlin, Germany; Jena University Hospital, Carl-Zeiss-Straße 12, D-07743 Jena, Germany.
Crit Care Clin. 2020 Jan;36(1):1-10. doi: 10.1016/j.ccc.2019.08.001. Epub 2019 Oct 21.
Sepsis is one of the oldest and most elusive syndromes in medicine that is still incompletely understood. Biomarkers may help to transform sepsis from a physiologic syndrome to a group of distinct biochemical disorders. This will help to differentiate between systemic inflammation of infectious and noninfectious origin and aid therapeutic decision making, hence improve the prognosis for patients, guide antimicrobial therapy, and foster the development of novel adjunctive sepsis therapies. To reach this goal requires increased systematic investigation that includes twenty-first century scientific approaches and technologies and appropriate clinical evaluation.
脓毒症是医学中最古老和最棘手的综合征之一，目前仍不完全了解。生物标志物可能有助于将脓毒症从一种生理综合征转变为一组不同的生化疾病。这将有助于区分感染性和非感染性来源的全身炎症，并有助于治疗决策，从而改善患者预后，指导抗菌治疗，并促进新的辅助脓毒症治疗方法的发展。要实现这一目标，需要增加包括 21 世纪科学方法和技术在内的系统研究，并进行适当的临床评估。
